Payment overview · 2025
General Payments
$476.14
25 reported records · 13 companies
Healthcare provider profile · identity verified
Donna Michelle Capps, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · KENLY, NC · NPI 1578665444
Verified facts
What the public records show
CMS Open Payments records show Donna Michelle Capps, M.D. received $476.14 in general payments during 2025 across 25 reported records.
ABBVIE INC. accounted for 21.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Gemtesa, Jardiance, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BYETTA as an associated drug or biological on 60 records involving 49 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Byetta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 193 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Synjardy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 193 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 158 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $102.82 | 21.6% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $54.81 | 11.5% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $53.21 | 11.2% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $44.91 | 9.4% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $42.83 | 9.0% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $35.68 | 7.5% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $32.18 | 6.8% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $20.02 | 4.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.61 | 4.1% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $19.42 | 4.1% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $17.31 | 3.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.15 | 3.6% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.19 | 3.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $476.14 | 25 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $83.37 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $67.76 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $56.53 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $44.91 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $42.83 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $42.83 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $35.68 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $29.93 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $29.93 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $23.28 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $23.28 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $20.02 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $19.61 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $19.45 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $19.42 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $17.62 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.62 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $17.31 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.15 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $14.56 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $14.56 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $14.56 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.47 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.47 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 62 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 193 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 53 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 158 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 74 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BYETTA open payments reported associated product |
CMS Open Payments — General Payments 60 supporting records · 49 recipient NPIs · example record 1206154618 |
Byetta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
193 | 34 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
74 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
193 | 34 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
158 | 27 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
62 | 11 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 402 | 104 |
| Amlodipine Besylate | Amlodipine Besylate | 354 | 91 |
| Levothyroxine Sodium | Levothyroxine Sodium | 298 | 77 |
| Metoprolol Succinate | Metoprolol Succinate | 252 | 60 |
| Pantoprazole Sodium | Pantoprazole Sodium | 242 | 63 |
| Furosemide | Furosemide | 233 | 61 |
| Omeprazole | Omeprazole | 216 | 63 |
| Lisinopril | Lisinopril | 204 | 52 |
| Gabapentin | Gabapentin | 201 | 62 |
| Jardiance | Empagliflozin | 193 | 34 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 183 | 52 |
| Pravastatin Sodium | Pravastatin Sodium | 169 | 42 |
| Losartan Potassium | Losartan Potassium | 162 | 44 |
| Ozempic | Semaglutide | 158 | 27 |
| Pioglitazone Hcl | Pioglitazone Hcl | 140 | 39 |
| Potassium Chloride | Potassium Chloride | 129 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 126 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 125 | 50 |
| Metformin Hcl | Metformin Hcl | 123 | 35 |
| Montelukast Sodium | Montelukast Sodium | 117 | 35 |
| Allopurinol | Allopurinol | 115 | 31 |
| Trazodone Hcl | Trazodone Hcl | 111 | 34 |
| Fluticasone Propionate | Fluticasone Propionate | 106 | 35 |
| Alprazolam | Alprazolam | 104 | 17 |
| Glimepiride | Glimepiride | 103 | 22 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 102 | 18 |
| Metformin Hcl Er | Metformin Hcl | 100 | 33 |
| Tamsulosin Hcl | Tamsulosin Hcl | 99 | 30 |
| Spironolactone | Spironolactone | 86 | 21 |
| Bupropion Xl | Bupropion Hcl | 84 | 23 |
| Simvastatin | Simvastatin | 84 | 20 |
| Carvedilol | Carvedilol | 76 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 76 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 74 | 22 |
| Ezetimibe | Ezetimibe | 74 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 74 | 12 |
| Alendronate Sodium | Alendronate Sodium | 71 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 71 | 21 |
| Pregabalin | Pregabalin | 71 | 12 |
| Lorazepam | Lorazepam | 70 | 12 |
| Hydrochlorothiazide | Hydrochlorothiazide | 67 | 18 |
| Prednisone | Prednisone | 67 | 27 |
| Buspirone Hcl | Buspirone Hcl | 66 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 65 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 64 | 20 |
| Eliquis | Apixaban | 62 | 11 |
| Meloxicam | Meloxicam | 62 | 21 |
| Sertraline Hcl | Sertraline Hcl | 61 | 18 |
| Ventolin Hfa | Albuterol Sulfate | 60 | 13 |
| Famotidine | Famotidine | 59 | 17 |
| Tramadol Hcl | Tramadol Hcl | 56 | 17 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 55 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 55 | 20 |
| Donepezil Hcl | Donepezil Hcl | 54 | 16 |
| Mounjaro | Tirzepatide | 53 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 51 | 16 |
| Oxycodone Hcl | Oxycodone Hcl | 51 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 49 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 46 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 46 | 12 |
| Baclofen | Baclofen | 43 | 13 |
| Ramipril | Ramipril | 43 | 11 |
| Atenolol | Atenolol | 40 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 40 | suppressed |
| Cephalexin | Cephalexin | 38 | 26 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 38 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 38 | 19 |
| Ondansetron Hcl | Ondansetron Hcl | 38 | 16 |
| Benazepril Hcl | Benazepril Hcl | 37 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 37 | suppressed |
| Celecoxib | Celecoxib | 36 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 36 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 36 | suppressed |
| Januvia | Sitagliptin Phosphate | 34 | suppressed |
| Telmisartan | Telmisartan | 34 | suppressed |
| Mirtazapine | Mirtazapine | 33 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 32 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 32 | suppressed |
| Tradjenta | Linagliptin | 32 | suppressed |
| Clonazepam | Clonazepam | 31 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 31 | suppressed |
| Valsartan | Valsartan | 31 | suppressed |
| Glipizide Er | Glipizide | 30 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 30 | suppressed |
| Aripiprazole | Aripiprazole | 29 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 29 | 11 |
| Topiramate | Topiramate | 29 | 14 |
| Trintellix | Vortioxetine Hydrobromide | 29 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 25 |
| Fenofibrate | Fenofibrate Nanocrystallized | 28 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 27 | suppressed |
| Lovastatin | Lovastatin | 27 | suppressed |
| Nystatin | Nystatin | 27 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 24 | suppressed |
| Myrbetriq | Mirabegron | 24 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 19 |
| Nitroglycerin | Nitroglycerin | 24 | 13 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Chlorthalidone | Chlorthalidone | 23 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 23 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 23 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 16 |
| Colchicine | Colchicine | 22 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 22 | 19 |
| Fluconazole | Fluconazole | 22 | 18 |
| Synjardy | Empagliflozin/Metformin Hcl | 22 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 21 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 20 | suppressed |
| Azithromycin | Azithromycin | 19 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | 17 |
| Gemtesa | Vibegron | 19 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 19 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 19 | suppressed |
| Methimazole | Methimazole | 19 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 19 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 13 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Etodolac | Etodolac | 13 | suppressed |
| Humalog | Insulin Lispro | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Amoxicillin | Amoxicillin | 12 | 11 |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Byetta | Exenatide | 12 | suppressed |
| Methadone Hcl | Methadone Hcl | 12 | suppressed |
| Mitigare | Colchicine | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 12 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 12 | suppressed |
| Indomethacin | Indomethacin | 11 | suppressed |
| Klor-Con M10 | Potassium Chloride | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $476.14 · 25 records | ABBVIE INC. | ABRYSVO, BREZTRI, COMIRNATY, Cologuard Collection Kit, ELIQUIS, EVENITY, GEMTESA, JARDIANCE, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, PROLIA, QULIPTA, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, XIFAXAN, YUPELRI, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error